Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation

Coronary artery disease and heart failure carry concurrent risk for atrial fibrillation and life-threatening ventricular arrhythmias. We review evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these arrhythmias. Mechanisms and clinical implicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Verrier, Richard L., Kumar, Kapil, Nieminen, Tuomo, Belardinelli, Luiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578672/
https://www.ncbi.nlm.nih.gov/pubmed/23220484
http://dx.doi.org/10.1093/europace/eus380
_version_ 1782260023469015040
author Verrier, Richard L.
Kumar, Kapil
Nieminen, Tuomo
Belardinelli, Luiz
author_facet Verrier, Richard L.
Kumar, Kapil
Nieminen, Tuomo
Belardinelli, Luiz
author_sort Verrier, Richard L.
collection PubMed
description Coronary artery disease and heart failure carry concurrent risk for atrial fibrillation and life-threatening ventricular arrhythmias. We review evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these arrhythmias. Mechanisms and clinical implications are discussed.
format Online
Article
Text
id pubmed-3578672
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-35786722013-02-22 Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation Verrier, Richard L. Kumar, Kapil Nieminen, Tuomo Belardinelli, Luiz Europace Review Coronary artery disease and heart failure carry concurrent risk for atrial fibrillation and life-threatening ventricular arrhythmias. We review evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these arrhythmias. Mechanisms and clinical implications are discussed. Oxford University Press 2013-03 2012-12-07 /pmc/articles/PMC3578672/ /pubmed/23220484 http://dx.doi.org/10.1093/europace/eus380 Text en Published on behalf of the European Society of Cardiology. © The Author 2012. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Verrier, Richard L.
Kumar, Kapil
Nieminen, Tuomo
Belardinelli, Luiz
Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
title Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
title_full Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
title_fullStr Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
title_full_unstemmed Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
title_short Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
title_sort mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578672/
https://www.ncbi.nlm.nih.gov/pubmed/23220484
http://dx.doi.org/10.1093/europace/eus380
work_keys_str_mv AT verrierrichardl mechanismsofranolazinesdualprotectionagainstatrialandventricularfibrillation
AT kumarkapil mechanismsofranolazinesdualprotectionagainstatrialandventricularfibrillation
AT nieminentuomo mechanismsofranolazinesdualprotectionagainstatrialandventricularfibrillation
AT belardinelliluiz mechanismsofranolazinesdualprotectionagainstatrialandventricularfibrillation

Ejemplares similares